Please login to the form below

Not currently logged in
Email:
Password:

P&G signs bioinformatics deal to speed new product research

Will use Eagle Genomics' software platform Eaglecore

edit-PG_logo 

Procter & Gamble (P&G) has signed a four-year agreement to use bioinformatics software to help boost the development of new products including pharmaceuticals, consumer goods and biofuels.

The firm will use Eagle Genomics' secure, cloud-based, Eaglecore platform to organise existing data and integrate existing data with new analysis from across the company.

Dr Abel Ureta-Vidal, CEO of Eagle, said: “Eaglecore is an extremely powerful platform and will have a major impact on P&G's approach to their current research projects.

“By using out platform, P&G will be able to better reference, manage and use all of their data to develop new insights and products, saving both time and development costs.”

The deal will see P&G take a four-year license for an undisclosed sum, which will include additional data curation services. The agreement follows a long partnership between the two companies involving Eagle's consultancy arm, which has been used to support past research.

Eagle, which allows large-scale genomics data and data generation technologies to be applied to world issues, was earlier this year awarded funding from the UK's Department of Health to develop proposals to help to with treating rare diseases and cancer.

Article by
Kirstie Pickering

12th December 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics